Looking forward in geriatric anxiety and depression: Implications of basic science for the future

American Journal of Geriatric Psychiatry

Volumn 13, Issue 12, 2005, Pages 1027-1040

  Gershenfeld, Howard K ^a   Philibert, Robert A ^b   Boehm, Gary W ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; GEFITINIB; LAMOTRIGINE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; TESTOSTERONE; THYROID HORMONE; EPIDERMAL GROWTH FACTOR; SEROTONIN TRANSPORTER;

AGRANULOCYTOSIS; ANXIETY DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG TARGETING; GENE FUNCTION; GENE INTERACTION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HORMONE ACTION; HUMAN; LUNG SMALL CELL CANCER; MAJOR DEPRESSION; MEDICAL RESEARCH; NEUROIMMUNOLOGY; NONHUMAN; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; STRESS; WEIGHT GAIN; AGED; ANXIETY; FORECASTING; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GERONTOPSYCHIATRY; METABOLISM; NERVE CELL NETWORK; THYROID GLAND; UNITED STATES;

AGED; ANXIETY; DEPRESSIVE DISORDER, MAJOR; EPIDERMAL GROWTH FACTOR; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERIATRIC PSYCHIATRY; HUMANS; LINKAGE (GENETICS); NERVE NET; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TESTOSTERONE; THYROID GLAND; UNITED STATES;

EID: 33645748250     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/00019442-200512000-00002     Document Type: Article

References (125)

1. Bourdon KH, Rae DS, Locke BZ, et al: Estimating the prevalence of mental disorders in U.S. adults from the Epidemiologic Catchment Area Survey. Public Health Rep 1992; 107:663-668
2. Regier DA, Rae DS, Narrow WE, et al: Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry 1998; (Suppl 34):24-28
3. Murray CJ, Lopez AD: Alternative Projections of Mortality and Disability by Cause, 1990-2020: Global Burden of Disease Study. Lancet 1997; 349(9064):1498-1504
4. Kessler RC, Berglund P, Demler O, et al: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289(23):3095-3105
5. Kessing LV: Endogenous, reactive, and neurotic depression: diagnostic stability and long-term outcome. Psychopathology 2004; 37:124-130
6. Solomon DA, Keller MB, Leon AC, et al: Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157:229-233
7. Solomon DA, Leon AC, Endicott J, et al: Psychosocial impairment and recurrence of major depression. Compr Psychiatry 2004; 45:423-430
8. Mueller TI, Kohn R, Leventhal N, et al: The course of depression in elderly patients. Am J Geriatr Psychiatry 2004; 12:22-29
9. Kendler KS, Neale MC, Kessler RC, et al: Major depression and generalized anxiety disorder: same genes, (partly) different environments? Arch Gen Psychiatry 1992; 49:716-722
10. Herman RM, Narasimhan M, Charney DS: Treatment-refractory depression: definitions and characteristics. Depress Anxiety 1997; 5:154-164
11. Bosker FJ, Westerink BH, Cremers TI, et al: Future antidepressants: what is in the pipeline and what is missing? CNS Drugs 2004; 18:705-732
12. Hindmarch I: Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry 2002; 17(suppl3):294-299
13. Donati RJ, Rasenick MM: G protein signaling and the molecular basis of antidepressant action. Life Sci 2003; 73:1-17
14. Bymaster FP, McNamara RK, Tran PV: New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opinion on Investigational Drugs 2003; 12:531-543
15. Delgado PL: Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000; 61(suppl6):7-11
16. Heninger GR, Delgado PL, Charney DS: The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine-depletion experiments in humans. Pharmacopsychiatry 1996; 29:2-11
17. Paul IA, Skolnick P: Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003; 1003:250-272
18. Freimer N, Sabatti C: The use of pedigree, sib-pair, and association studies of common diseases for genetic mapping and epidemiology. Nat Genet 2004; 36:1045-1051
19. Flint J: Analysis of quantitative trait loci that influence animal behavior. J Neurobiol 2003; 54:46-77
20. Agid O, Kohn Y, Lerer B: Environmental stress and psychiatric illness. Biomed Pharmacother 2000; 54:135-141
21. Risch NJ: Searching for genetic determinants in the new millennium. Nature 2000; 405(6788):847-856
22. Farrer LA, Cupples LA, Haines JL, et al: Effects of age, sex, and ethnicity on the association between apolipoprotein-E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. JAMA 1997; 278:1349-1356
23. Whisnant JP, Brown RD, Petty GW, et al: Comparison of population-based models of risk factors for TIA and ischemic stroke. Neurology 1999; 53:532-536
24. Sacco RL: Risk factors and outcomes for ischemic stroke. Neurology 1995; 45(suppl1):S10-S14
25. Andrewes FW: Disease in the light of evolution. Lancet 1926; 1:1075
26. Abkevich V, Camp NJ, Hensel CH, et al: Predisposition locus for major depression at chromosome 12q22-12q23.2. Am J Hum Genet 2003; 73:1271-1281
27. Fullerton J, Cubin M, Tiwari H, et al: Linkage analysis of extremely discordant and concordant sibling pairs identifies quantitative-trait loci that influence variation in the human personality trait neuroticism. Am J Hum Genet 2003; 72:879-890
28. Livesley WJ, Jang KL, Vernon PA: Phenotypic and genetic structure of traits delineating personality disorder. Arch Gen Psychiatry 1998; 55:941-948
29. Kendler KS, Gardner CO: Boundaries of major depression: an evaluation of DSM-IV criteria. Am J Psychiatry 1998; 155:172-177
30. Kendler KS, Kuhn J, Prescott CA: The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression. Am J Psychiatry 2004; 161:631-636
31. Helgadottir A, Manolescu A, Thorleifsson G, et al: The gene encoding 5-lipoxygenase-activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233-239
32. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al: Neuregulin-1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71:877-892
33. Altmuller J, Palmer LJ, Fischer G, et al: Genome-wide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 2001; 69:936-950
34. Stefansson H, Sarginson J, Kong A, et al: Association of neuregulin-1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003; 72:83-87
35. Stefansson H, Steinthorsdottir V, Thorgeirsson TE, et al: Neuregulin-1 and schizophrenia. Ann Med 2004; 36:62-71
36. Falls DL: Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003; 284:14-30
37. A receptors at the hippocampal inhibitory synapse. Hippocampus 2004; 14:337-344
38. Botstein D, Risch N: Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat Genet 2003; 33(suppl):228-237
39. Hirschhorn JN, Lohmueller K, Byrne E, et al: A comprehensive review of genetic association studies. Genet Med 2002; 4:45-61
40. Cardon LR, Palmer LJ: Population stratification and spurious allelic association. Lancet 2003; 361(9357):598-604
41. Hamer D, Sirota L: Beware the chopsticks gene. Mol Psychiatry 2000; 5:11-13
42. Jorm AF, Easteal S: Assessing candidate genes as risk factors for mental disorders: the value of population-based epidemiological studies. Soc Psychiatry Psychiatr Epidemiol 2000; 35:1-4
43. Hinds DA, Stokowski RP, Patil N, et al: Matching strategies for genetic-association studies in structured populations. Am J Hum Genet 2004; 74:317-325
44. Austin MA, Harding S, McElroy C: Genebanks: a comparison of eight proposed international genetic databases. Community Genetics 2003; 6:37-45
45. Godard B, Marshall J, Laberge C, et al: Strategies for consulting with the community: the cases of four large-scale genetic databases. Sci Eng Ethics 2004; 10:457-477
46. Bunney WE, Bunney BG, Vawter MP, et al: Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders. Am J Psychiatry 2003; 160:657-666
47. Evans SJ, Choudary PV, Neal CR, et al: Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A 2004; 101:15506-15511
48. Henn FA, Vollmayr B: Neurogenesis and depression: etiology or epiphenomenon? Biol Psychiatry 2004; 56:146-150
49. Duman RS: Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Medicine 2004; 5:11-25
50. Kempermann G, Kronenberg G: Depressed new neurons: adult hippocampal neurogenesis and a cellular-plasticity hypothesis of major depression. Biol Psychiatry 2003; 54:499-503
51. Hashimoto K, Shimizu E, Iyo M: Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004; 45:104-114
52. Nakatomi H, Kuriu T, Okabe S, et al: Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 2002; 110:429-441
53. Carlson CS, Eberle MA, Kruglyak L, et al: Mapping complex disease loci in whole-genome association studies. Nature 2004; 429(6990):446-452
54. Neale BM, Sham PC: The future of association studies: gene-based analysis and replication. Am J Hum Genet 2004; 75:353-362
55. Murphy DL, Li Q, Engel S, et al: Genetic perspectives on the serotonin transporter. Brain Res Bull 2001; 56:487-494
56. Munafo MR, Clark TG, Moore LR, et al: Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis. Mol Psychiatry 2003; 8:471-484
57. Hariri AR, Mattay VS, Tessitore A, et al: Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297(5580):400-403
58. Caspi A, Sugden K, Moffitt TE, et al: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301(5631):386-389
59. [123I]β-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004; 161:525-531
60. 1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002; 416(6879):396-400
61. Hosford DA, Lai EH, Riley JH, et al: Pharmacogenetics to predict drug-related adverse events. Toxicol Pathol 2004; 32(suppl1):9-12
62. Weston AD, Hood L: Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004; 3:179-196
63. Gurwitz D, Weizman A: Personalized psychiatry: a realistic goal. Pharmacogenomics 2004; 5:213-217
64. Carr KM, Rosenblatt K, Petricoin EF, et al: Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics 2004; 1:134-140
65. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676):1497-1500
66. Sordella R, Bell DW, Haber DA, et al: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305(5687):1163-1167
67. Minna JD, Gazdar AF, Sprang SR, et al: Cancer: a bulls' eye for targeted lung cancer therapy. Science 2004; 304(5676):1458-1461
68. Liu X, Gershenfeld HK: Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biol Psychiatry 2001; 49:575-581
69. Liu X, Gershenfeld HK: An exploratory factor analysis of the Tail Suspension Test in 12 inbred strains of mice and an F2 intercross. Brain Res Bull 2003; 60:223-231
70. Schatzberg AF, Kremer C, Rodrigues HE, et al: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10:541-550
71. Cussons AJ, Bhagat CI, Fletcher SJ, Walsh JP: Brown-Sequard revisited: a lesson from history on the placebo effect of androgen treatment. Med J Aust 2002; 177:678-679
72. Freeman ER, Bloom DA, McGuire EJ: A brief history of testosterone. J Urol 2001; 165:371-373
73. Pope HG Jr, Cohane GH, Kanayama G, et al: Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160:105-111
74. Carnahan RM, Perry PJ: Depression in aging men: the role of testosterone. Drugs Aging 2004; 21:361-376
75. Altshuler LL, Bauer M, Frye MA, et al: Does thyroid supplementation accelerate tricyclic antidepressant response? a review and metaanalysis of the literature. Am J Psychiatry 2001; 158:1617-1622
76. Joffe RT, Singer W, Levitt AJ, et al: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387-393
77. Maglich JM, Sluder A, Guan X, et al: Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans, and Drosophila genomes. Genome Biol 2001; 2:RESEARCH0029
78. Aranda A, Pascual A: Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81:1269-1304
79. Ito M, Yuan CX, Malik S, et al: Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell 1999; 3:361-370
80. Taatjes DJ, Naar AM, Andel F 3rd, et al: Structure, function, and activator-induced conformations of the CRSP coactivator (see comments). Science 2002; 295(5557):1058-1062
81. Naar AM, Beaurang PA, Zhou S, et al: Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature 1999; 398(6730):828-832
82. Rachez C, Lemon BD, Suldan Z, et al: Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999; 398(6730):824-828
83. Bourbon HM, Aguilera A, Ansari AZ, et al: A unified nomenclature for protein subunits of mediator complexes linking transcriptional regulators to RNA polymerase II. Mol Cell 2004; 14:553-557
84. Ito M, Roeder RG: The TRAP/SMCC/Mediator complex and thyroid hormone receptor function. Trends in Endocrinology and Metabolism 2001; 12:127-134
85. Tan RS, Salazar JA: Risks of testosterone replacement therapy in ageing men. Expert Opinion on Drug Safety 2004; 3:599-606
86. Theisen C: IOM report targets testosterone therapy. J Natl Cancer Inst 2004; 96:259
87. Spinks R, Sandhu HK, Andreasen NC, et al: Association of the HOPA 12bp allele with a large X-chromosome haplotype and positive-symptom schizophrenia. Am J Med Genet 2004; 127B(1):20-27
88. Riggs BL, Hartmann LC: Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618-629
89. Smith CL, O'Malley BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004; 25:45-71
90. Yu S, Matsusue K, Kashireddy P, et al: Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma-1 (PPARgamma-1) overexpression. J Biol Chem 2003; 278:498-505
91. Krotkiewski M: Thyroid hormones and treatment of obesity. Int J Obes Relat Metab Disord 2000; 24(suppl2):S116-S119
92. Ludewig AH, Kober-Eisermann C, Weitzel C, et al: A novel nuclear receptor/coregulator complex controls C. elegans lipid metabolism, larval development, and aging. Genes Dev 2004; 18:2120-2133
93. Chakraborty TR, Gore AC: Aging-related changes in ovarian hormones, their receptors, and neuroendocrine function. Exp Biol Med 2004; 229:977-987
94. Irwin M: Depression and immunity, in Psychoneuroimmunology. Edited by Ader R, Felten D, Cohen N. New York, Academic Press, 2004, pp 383-398
95. Anisman H, Merali Z: Cytokines, stress, and depressive illness: brain-immune interactions. Ann Med 2003; 35:2-11
96. Capuron L, Dantzer R: Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003; 17(suppl1):S119-S124
97. Dantzer R: Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004; 500:399-411
98. Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003; 17:13-19
99. Barton GM, Medzhitov R: Toll-like receptor-signaling pathways. Science 2003; 300(5625):1524-1525
100. Beutler B: Innate immunity: an overview. Mol Immunol 2004; 40:845-859
101. Yirmiya R: Endotoxin produces a depressive-like episode in rats. Brain Res 1996; 711:163-174
102. Rivier C: The hypothalamo-pituitary-adrenal axis response to immune signals, in Psychoneuroimmunology. Edited by Ader R, Felten D, Cohen N. New York, Academic Press, 2001, pp 633-648
103. Lapchak PA, Araujo DM, Hefti F: Systemic interleukin-1 beta decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience 1993; 53:297-301
104. Castanon N, Bluthe RM, Dantzer R: Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1β in the rat. Psychopharmacology (Berl) 2001; 154:50-60
105. Yirmiya R, Pollak Y, Barak O, et al: Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001; 24:531-544
106. Zorrilla EP, Luborsky L, McKay JR, et al: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15:199-226
107. Maes M, Meltzer HY, Bosmans E, et al: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2, and transferrin receptor in major depression. J Affect Disord 1995; 34:301-309
108. Schlatter J, Ortuno F, Cervera-Enguix S: Monocytic parameters in patients with dysthymia versus major depression. J Affect Disord 2004; 78:243-247
109. Haack M, Hinze-Selch D, Fenzel T, et al: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33:407-418
110. Capuron L, Gumnick JF, Musselman DL, et al: Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26:643-652
111. Hauser P, Khosla J, Aurora H, et al: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7:942-947
112. Kahl KG, Kruse N, Faller H, et al: Expression of tumor necrosis factor-α and interferon-γ mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002; 27:671-681
113. Trzonkowski P, Mysliwska J, Godlewska B, et al: Immune consequences of the spontaneous pro-inflammatory status in depressed elderly patients. Brain Behav Immun 2004; 18:135-148
114. O'Connor KA, Johnson JD, Hansen MK, et al: Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res 2003; 991:123-132
115. Nguyen KT, Deak T, Will MJ, et al: Time-course and corticosterone sensitivity of the brain, pituitary, and serum interleukin-1β protein response to acute stress. Brain Res 2000; 859:193-201
116. Johnson JD, O'Connor KA, Watkins LR, et al: The role of IL-1β in stress-induced sensitization of proinflammatory cytokine and corticosterone responses. Neuroscience 2004; 127:569-577
117. Longo DL: Immunology of aging, in Fundamental Immunology. Edited by Paul WE. Philadelphia, PA, Lippincott Williams & Wilkins, 2003, pp 1043-1075
118. Suarez EC: Joint effect of hostility and severity of depressive symptoms on plasma interleukin-6 concentration. Psychosom Med 2003; 65:523-527
119. Neubig RR, Siderovski DP: Regulators of G-protein signaling as new central nervous system drug targets. Nat Rev Drug Discov 2002; 1:187-197
120. Liebmann C: G protein-coupled receptors and their signaling pathways: classical therapeutical targets susceptible to novel therapeutic concepts. Curr Pharm Des 2004; 10:1937-1958
121. Oliveira-Dos Santos AJ, Matsumoto G, Snow BE, et al: Regulation of T-cell activation, anxiety, and male aggression by RGS2. Proc Natl Acad Sci U S A 2000; 97(22):12272-12277
122. Yalcin B, Willis-Owen SA, Fullerton J, et al: Genetic dissection of a behavioral quantitative trait locus shows that Rgs-2 modulates anxiety in mice. Nat Genet 2004; 36:1197-1202
123. Monje ML, Toda H, Palmer TD: Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302(5651):1760-1765
124. Ulevitch RJ: Therapeutics targeting the innate immune system. Nat Rev Immunol 2004; 4:512-520
125. Ortega y Gassett J: The barbarism of specialization, in The Sacred Beetle and Other Great Essays in Science. Edited by Gardner M. New York, Meridian Books, 1984, pp 121-129